Combining Sertraline with Rasagiline: Risk of Serotonin Syndrome
The combination of sertraline (an SSRI) with rasagiline (a selective MAO-B inhibitor) is NOT recommended and carries significant risk of potentially life-threatening serotonin syndrome, though this combination can be used with extreme caution in select circumstances if absolutely necessary. 1
FDA Drug Label Position (Highest Priority)
The FDA label for rasagiline explicitly states that concomitant use with SSRIs is NOT recommended 1. The label warns that:
- Potentially life-threatening serotonin syndrome has been reported in postmarketing surveillance with rasagiline combined with antidepressants 1
- At least 14 days should elapse between discontinuation of rasagiline and initiation of any SSRI 1
- Conversely, at least 14 days should elapse after stopping an SSRI before starting rasagiline (5 weeks for fluoxetine due to its long half-life) 1
The rasagiline label acknowledges that clinical trials included small numbers of patients on SSRIs (n=141), but emphasizes this exposure was "not adequate to rule out the possibility of an untoward reaction" 1.
Clinical Guideline Perspective
Current guidelines on serotonin syndrome clearly state that MAO inhibitors should be avoided in combination with any other serotonergic drug 2. While these guidelines primarily reference non-selective MAOIs, they emphasize that:
- MAOIs "play a role in most cases of serotonin syndrome" 2
- Concomitant administration of any SSRIs with any MAO inhibitors is contraindicated because of increased risk of serotonin syndrome 2
- Serotonin syndrome can result in death, with advanced symptoms including fever, seizures, arrhythmias, and unconsciousness 2
Real-World Evidence: The Nuanced Picture
Despite the strong warnings, research evidence presents a more complex reality:
Large-scale safety data suggests the combination may be better tolerated than expected:
- The STACCATO study (n=1,504 Parkinson's patients) found zero cases of serotonin syndrome with rasagiline plus antidepressants (74.5% were SSRIs, mean duration 50-53 weeks) 3
- The ADAGIO study (n=191 patients on antidepressants with rasagiline) reported no serious adverse events suggestive of serotonin syndrome and actually showed improvement in depression and other non-motor symptoms 4
- A 2018 systematic review found serotonin syndrome occurs "rarely" with MAO-B inhibitor/SSRI combinations, with the combination being "well tolerated" in most cases 5
However, case reports document real risk:
- 17 case reports describe serotonin syndrome with SSRI plus selegiline or rasagiline combinations 5
- A 2026 fatal case report describes a 72-year-old who developed fatal serotonin syndrome with sequential SSRI use (sertraline then escitalopram) while on stable rasagiline, complicated by CYP2D6*10/*10 genotype 6
- Recent pharmacovigilance data (2026) shows strong signals for serotonin syndrome with SSRI-opioid combinations (ROR 95.94), highlighting the broader risk of combining serotonergic agents 7
Clinical Decision Algorithm
If the combination is absolutely necessary (e.g., established Parkinson's disease with treatment-resistant depression):
Use sertraline or citalopram preferentially among SSRIs, as they may have more favorable profiles 5
Keep SSRI dose at the lower end of therapeutic range and do not exceed recommended doses of either medication 5
Monitor intensively for serotonin syndrome symptoms, especially in the first 24-48 hours after initiation or dose changes 2:
- Mental status changes: confusion, agitation, anxiety, hypomania
- Neuromuscular hyperactivity: tremors, clonus (most specific finding), hyperreflexia, muscle rigidity
- Autonomic hyperactivity: hypertension, tachycardia, diaphoresis, hyperthermia, diarrhea
Consider pharmacogenetic testing (particularly CYP2D6 status) in patients requiring this combination, as genetic factors may increase risk 6
Avoid in patients with:
- Multiple other serotonergic medications
- History of serotonin syndrome
- Genetic polymorphisms affecting drug metabolism (if known)
Critical Pitfalls to Avoid
- Do not assume selective MAO-B inhibitors are completely safe with SSRIs - while selectivity reduces risk, it doesn't eliminate it, especially at higher doses or in genetically susceptible individuals 1, 6
- Do not overlook the 14-day washout period when switching between these medications 1
- Do not miss subtle early signs - up to 30% of adverse events may occur >300 days after initiation, requiring sustained vigilance 7
- Do not combine with additional serotonergic agents (tramadol, fentanyl, other opioids, triptans, linezolid) as this dramatically increases risk 8, 7, 9
Bottom Line
The safest approach is to avoid this combination entirely and use alternative treatments. If clinical circumstances absolutely require concurrent use, proceed only with informed consent, lowest effective doses, intensive monitoring, and immediate discontinuation at first sign of serotonin syndrome symptoms. The FDA's "not recommended" stance should be the default position in clinical practice, with rare exceptions made only after careful risk-benefit analysis in individual cases.